Sanofi’s Enjaymo, the only approved drug therapy for a rare and debilitating ... While this disease is not cancer, its progression is similar to that of lymphoma, a cancer of the lymph nodes.

Sept 20 - The U.S. Food and Drug Administration said on Friday it has approved the use of a drug combination along with Sanofi's ... its commitment to oncology drug development even after a ...

The FDA has approved Sarclisa (isatuximab) as a first-line therapy for blood cancer multiple myeloma as a combination regimen ...

Having already been on a winding journey, Enjaymo, which Sanofi acquired through a 2018 buyout of Bioverativ, is now headed to Recordati as part of a deal announced Friday.

Recordati will acquire global rights to Enjaymo from Sanofi for $825M, boosting its rare disease portfolio. The deal includes ...

Sanofi agreed to pay up to 320 million euros ... bet by a major pharmaceutical company on an emerging class of cancer drugs known as radiopharmaceuticals, which use radioactive substances to ...

Since an initial FDA go-ahead in 2020, Sanofi’s Sarclisa has been specifically approved for patients with previously treated multiple myeloma. That changed Friday. The FDA has approved Sarclisa ...

Sanofi is following several of its big pharma ... submission as a treatment for a rare type of gastrointestinal cancer. According to deal terms announced Thursday, Sanofi is paying €100 million ...

Following the FDA's green light for a combo regimen of Sanofi’s Sarclisa in patients with newly diagnosed multiple myeloma ...

Among the large drugmakers, Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer are worth retaining in one’s portfolio.

Recordati has reached an agreement with Sanofi for acquiring the worldwide rights to Enjaymo, the only approved treatment ...